MicroRNA Regulation of Chronic Inflammation During Aging

NCT ID: NCT05392582

Last Updated: 2025-12-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-11-12

Study Completion Date

2028-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an observational study enrolling healthy individuals aged 18-35 and 65y and older to determine the health of immune cells in the blood and how these cells create inflammation and effect health as we age. It is hoped that once the nature of this relationship has been discovered we can more effectively design therapies to reduce this inflammation.

The enrollment goal is 40 participants. The study will occur over the course of 1 month which will include a screening visit and a second visit where the participants will undergo an oral glucose tolerance test, blood draws and leg strength \& exercise tests.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

We will recruit healthy, non-obese (\<30kg/m2 BMI) younger (N=20; 18-35y) and older (N=20; \>65y) male and female participants (as determined by sample size calculation) in the Salt Lake City area.

1. VISIT 1 (Screening, visit duration: 1 hour): Once the participant is identified, they will be scheduled for a screening visit at the CTSI (421 Wakara Way) to see if they meet incl/excl criteria and to sign an informed consent document. As part of the visit, Upon arrival, we will gather basic health information such as height, weight, blood pressure, and heart rate.

* Participant will undergo the following procedures: a blood screening (30ml of blood collected)
* For older cohort: The clinical frailty scale (CFS) and Mini-Cog© cognitive assessment
2. VISIT 2 (visit duration: 3 hours) Following a 10h fast, participants will arrive in the morning. Upon arrival, we may gather basic health information from the participant such as height, weight, blood pressure, and heart rate. The procedures to take place at this visit are as follows:

* 120 mL serum blood sample collection. Samples will be used to identify the immune cell populations in the blood, regulators of these immune cells and how these cells function.
* Oral glucose tolerance test (OGTT)- participants will be asked to complete a test to determine their blood sugar levels. We will ask them to drink a sugary liquid (glucola) and then rest quietly while we measure changes in their blood sugar levels. We will draw 20 ml of blood during this test (\~1 tablespoon). OGTT will take approximately 2hours.
* Leg strength tests at the SMERF facility. Isometric strength will be assessed in both legs with a maximal voluntary isometric contraction effort developed by the knee extensors (quadriceps) on a isokinetic dynamometer. For lower extremity extension power testing a Nottingham power rig will be used. Total time for these tests will take 45 minutes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Inflammation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Young

Young healthy adult participants

No interventions assigned to this group

Older

Older healthy adult participants

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age between 18 - 35y; 65y and older
2. BMI: \<30 kg/m2
3. Ability to sign informed consent
4. For older participant group: Clinical Frailty Scale score \< 3 and Mini-Cog score \> 3
5. Good general medical health, ambulatory and in independent living setting

Exclusion Criteria

* History of cardiovascular disease (e.g., CHF, CAD, MI, CVA)
* History of endocrine or metabolic disease such as hypo/hyperthyroidism and diabetes (Treated hypo/hyperthyroid for at least 6 months will be permitted)
* History of kidney disease or failure (CKD \> stage 4)
* History of vascular disease
* Uncontrolled hypertension - Elevated systolic pressure \>150 or a diastolic blood pressure \> 100
* Cancer or history of successfully treated cancer (less than 1 year) other than basal cell carcinoma
* Chronic systemic corticosteroid use (≥ 2 weeks) within 4 weeks of enrollment and for study duration (intra-articular/topical/inhaled therapeutic or physiologic doses of corticosteroids will be permitted)
* Chronic anti-inflammatory medication use (≥ 2 weeks) within 4 weeks of enrollment
* Chronic inflammatory conditions (e.g., Rheumatoid Arthritis, Crohn's, fibromyalgia, lupus, colitis) HIV, Hepatitis B and C
* History of stroke with motor disability
* A recent history (\<12 months) of GI bleed
* History of liver disease or AST/ALT 2 times above the normal limit
* History of respiratory disease (acute upper respiratory infection, history of chronic lung disease)
* Current smokers or current tobacco use
* Current pregnancy as determined by positive pregnancy test
* Any staff members who report directly to the principal investigators.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Utah

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Micah Drummond

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Micah Drummond

Role: PRINCIPAL_INVESTIGATOR

The University of Utah

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The University of Utah

Salt Lake City, Utah, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Micah Drummond, PhD

Role: CONTACT

801-213-2737

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Micah Drummond, PhD

Role: primary

801-213-2737

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

153158

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Inflammatory Response to OMT
NCT06820684 COMPLETED NA